Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Next Previous
Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toremifene (Primary)
  • Indications Fracture; Male osteoporosis; Prostate cancer; Vertebral fracture
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms TREAT-1
  • Sponsors GTx

    • Most Recent Events

    • 01 Feb 2014 Results of an analysis of free serum testosterone levels at baseline in men who had undergone orchiectomy (n=114) presented at the 2014 Genitourinary Cancers Symposium.
    • 09 Jun 2010 Results of this trial have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010), according to a GTx media release.
    • 28 May 2010 Additional study results of a substudy evaluating PSA progression-free survival will be presented at the American Urological Association Annual Meeting, according to a GTx media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top